Interview with David Veitch, CEO of Basilea Pharmaceutica

Interview with David Veitch, CEO of Basilea Pharmaceutica

Basilea Pharmaceutica — 9 videos in collection

More on this equity

Basilea Pharmaceutica is a Switzerland-based biotech specialising in the anti-fungal/anti-infective niche, where it has been able to commercialise via partnerships with large pharma. The company’s lead assets are Cresemba (or isavuconazole – an antifungal therapy) and Zevtera (or ceftobiprole – an antibiotic therapy). The company’s expanding portfolio includes preclinical assets and the recent antifungal Phase III-ready asset addition, Fosmanogepix.


You may also be interested in these:

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free